SCHEMBL6132849

SCHEMBL6132849

FC1COCCN(Cc2ccccc2)C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 6/20 0.51
SIGMAR1 Q99720 2/20 0.47
FUCA1 P04066 2/20 0.46
LTA4H P09960 1/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C9 P11712 1/20 0.46
ALDH1A1 P00352 2/20 0.45
CYP2C19 P33261 1/20 0.45
DRD2 P14416 1/20 0.45
DRD3 P35462 1/20 0.45
HRH3 Q9Y5N1 1/20 0.45
KDM4E B2RXH2 1/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
POLB P06746 1/20 0.44
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
BACE1 P56817 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2459044 0.81 SIGMAR1 (0.65) DRD4SIGMAR1FUCA1CYP1A2CYP3A4
SCHEMBL13597304 0.81 ACHE (0.54) DRD4SIGMAR1FUCA1CYP1A2CYP3A4
SCHEMBL3780157 0.80 ACHE (0.59) DRD4SIGMAR1LTA4HCYP1A2CYP3A4
SCHEMBL3789159 0.80 ACHE (0.59) DRD4SIGMAR1LTA4HCYP1A2CYP3A4
SCHEMBL1848011 0.80 ACHE (0.59) DRD4SIGMAR1LTA4HCYP1A2CYP3A4
SCHEMBL13597305 0.79 DRD4 (0.49) DRD4SIGMAR1FUCA1CYP1A2CYP3A4
Hydrochloric Acid SCHEMBL27453916 0.78 ACHE (0.58) DRD4SIGMAR1LTA4HCYP1A2CYP3A4
SCHEMBL102338 0.77 SIGMAR1 (0.71) DRD4SIGMAR1ALDH1A1HRH3KDM4E
SCHEMBL6200777 0.77 SIGMAR1 (0.71) DRD4SIGMAR1ALDH1A1HRH3KDM4E
SCHEMBL1176957 0.77 KDM4E (0.50) DRD4CYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013095275-A1 NOVEL HEPATITIS C VIRUS INHIBITORS MEDIVIR AB (SE) 2013-06-27 WO disclosed
US-6924278-B2 Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-08-02 US disclosed
US-20050027121-A1 Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-02-03 US disclosed
US-20030114668-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-19 US disclosed
EP-0993457-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-19 EP disclosed
WO-1998057954-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050027121-A1 Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists TAC3, TACR1, SSTR5 DRD4 1116/4885SIGMAR1 1572/4885FUCA1 2785/4885
US-20030114668-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS TACR1, NPSR1, SSTR2 DRD4 522/4885SIGMAR1 670/4885FUCA1 2412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.